Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
COVID-19 is currently one of the serious public health challenges worldwide, and there is a
great need to develop effective treatments. Paxlovid is a Pfizer-developed oral new drug for
the treatment of COVID-19. Paxlovid, which is used to treat adult patients with mild to
moderate COVID-19 who have high-risk factors for progression to severe disease, was
conditionally approved for marketing in the United States and China in December 2021 and
February 2022, respectively. Clinical trials have shown that this drug can significantly
reduce the progression from mild to severe disease and the rate of hospitalization and
mortality. However, due to the limitations of clinical trials in the subject selection, there
is still insufficient knowledge about the efficacy and safety of Paxlovid in a real-world
population. Relevant studies on this drug in real-world people, especially in Chinese
populations, have not been reported. Therefore, this study was designed to investigate the
efficacy and safety of Paxlovid on sufferers of COVID-19 through a retrospective, real-world
analysis.